Newby DE - Search Results

1

Vascular dysfunction in chronic obstructive pulmonary disease.

Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, Newby DE, Macnee W. Maclay JD, et al. Among authors: newby de. Am J Respir Crit Care Med. 2009 Sep 15;180(6):513-20. doi: 10.1164/rccm.200903-0414OC. Epub 2009 Jun 19. Am J Respir Crit Care Med. 2009. PMID: 19542477

2

An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium.

Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. Newby DE, et al. Thromb Haemost. 1997 Oct;78(4):1242-8. Thromb Haemost. 1997. PMID: 9364992

3

The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man.

Newby DE, Wright RA, Dawson P, Ludlam CA, Boon NA, Fox KA, Webb DJ. Newby DE, et al. Cardiovasc Res. 1998 May;38(2):485-92. doi: 10.1016/s0008-6363(98)00017-0. Cardiovasc Res. 1998. PMID: 9709410 Clinical Trial.

4

Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction.

Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, Webb DJ. Newby DE, et al. Circulation. 1999 Mar 23;99(11):1411-5. doi: 10.1161/01.cir.99.11.1411. Circulation. 1999. PMID: 10086962

5

Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.

Goodfield NE, Newby DE, Ludlam CA, Flapan AD. Goodfield NE, et al. Among authors: newby de. Circulation. 1999 Jun 15;99(23):2983-5. doi: 10.1161/01.cir.99.23.2983. Circulation. 1999. PMID: 10368114 Clinical Trial.

6

Local and systemic effects of intra-arterial desmopressin in healthy volunteers and patients with type 3 von Willebrand disease. Role of interleukin-6.

Newby DE, Stewart A, Witherow FN, Grieve S, Dawson P, Fox KA, Webb DJ, Ludlam CA. Newby DE, et al. Thromb Haemost. 2000 Aug;84(2):195-203. Thromb Haemost. 2000. PMID: 10959689

7

Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man.

Labinjoh C, Newby DE, Dawson P, Johnston NR, Ludlam CA, Boon NA, Webb DJ. Labinjoh C, et al. Among authors: newby de. Cardiovasc Res. 2000 Sep;47(4):707-14. doi: 10.1016/s0008-6363(00)00126-7. Cardiovasc Res. 2000. PMID: 10974219 Clinical Trial.

8

Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis.

Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, Fox KA, Boon NA. Newby DE, et al. Circulation. 2001 Apr 17;103(15):1936-41. doi: 10.1161/01.cir.103.15.1936. Circulation. 2001. PMID: 11306520 Clinical Trial.

9

Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.

Labinjoh C, Newby DE, Pellegrini MP, Johnston NR, Boon NA, Webb DJ. Labinjoh C, et al. Among authors: newby de. J Am Coll Cardiol. 2001 Nov 1;38(5):1402-8. doi: 10.1016/s0735-1097(01)01562-5. J Am Coll Cardiol. 2001. PMID: 11691515 Free article. Clinical Trial.

10

Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo.

Newby DE, Witherow FN, Wright RA, Bloomfield P, Ludlam CA, Boon NA, Fox KA, Webb DJ. Newby DE, et al. Heart. 2002 Jan;87(1):48-53. doi: 10.1136/heart.87.1.48. Heart. 2002. PMID: 11751664 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

858 results

Search Page

Filters